10-OH-HHC: Legal or Banned?

Legality of 10-OH-HHC in France: 2026 Update

In-depth analysis of the legal status of 10-OH-HHC (10-hydroxy-hexahydrocannabinol) in France in light of recent ANSM decisions, supported by official sources and professional best practices.

Introduction

10-OH-HHC (10-hydroxy-hexahydrocannabinol) is a cannabinoid-family molecule derived from HHC (hexahydrocannabinol). Having emerged recently on the European market, it has attracted growing attention among scientific, regulatory, and commercial stakeholders due to an ambiguous legal status. This article provides a comprehensive overview of the regulatory situation for 10-OH-HHC in France, notably based on an official reply issued by the French National Agency for the Safety of Medicines and Health Products (ANSM) in October 2024.

Chemical structure and properties

10-OH-HHC is a hydroxylated metabolite of HHC, obtained either through natural enzymatic transformation in the body or via laboratory synthesis processes. It differs from HHC through the presence of a hydroxyl group (OH) at position 10 on the benzochromene core. This modification affects polarity, bioavailability, and potentially its pharmacodynamic effects. Scientific data remains limited, but preliminary work suggests an activity profile close to HHC, while being less potent than THC.

French regulatory framework

In May 2024, ANSM published an update to the list of narcotic substances, adding several synthetic cannabinoids such as HHC, HHC-acetate, and certain analogues. However, 10-OH-HHC was not explicitly listed.

This statement, made public by GBZ420.com, has been interpreted as temporary confirmation that 10-OH-HHC is legal in France. It is important to note, however, that this position may evolve depending on scientific developments or misuse associated with the molecule.

Legal and commercial considerations

In the absence of an explicit listing as a narcotic, the sale of 10-OH-HHC may remain possible in France, provided that applicable rules for market placement (e.g., as technical products or within relevant regulatory categories) are respected. Sellers should ensure full traceability, provide independent laboratory analyses (COA), and comply with European chemical regulations (REACH).

GBZ420’s role in responsible information

GBZ420 differentiates itself by publishing official documents and providing transparent information to customers. By offering 10-OH-HHC backed by analyses and aligned with national guidance, the company positions itself as a legitimate and responsible player in the alternative cannabinoid market.

Regulatory outlook

As with any emerging cannabinoid, the status of 10-OH-HHC may evolve rapidly. French authorities, in coordination with European monitoring bodies, closely track the emergence of new psychoactive substances. A future listing of 10-OH-HHC cannot be ruled out. Professionals should maintain active regulatory monitoring through official channels.

Conclusion

10-OH-HHC is not currently classified as a narcotic in France. This situation, referenced by ANSM in October 2024, opens a framework for controlled commercialization. Nonetheless, continuous regulatory monitoring and responsible commercial practices are essential for all stakeholders. Platforms like gbz420.com play a useful role by sharing practical, documented information for professionals and consumers.

Sources:

• Official ANSM reply regarding 10-OH-HHC, 16 October 2024 (document accessible on gbz420.com)
• ANSM: new cannabinoids added to the narcotics list